Splicing is a cellular process essential for mRNA biogenesis. There are two types of splicing: constitutive and alternative splicing. During constitutive splicing, non-coding intron sequences are removed and exonic coding sequences are spliced together to form mature mRNAs. Alternative splicing can maximize the coding capacity of the genome by specific alternative selection of exons from multi-exon metazoan pre-mRNAs. Splicing is a tightly regulated process, so when control is lost disease may occur. SR proteins (serine/argininerich proteins) are a family of highly conserved splicing regulators that are also involved in other steps in RNA biogenesis and expression. Many viruses have evolved to utilize the cellular splicing machinery to enhance their proteome from a limited number of genes. HPV (human papillomavirus) is an example of one such virus. The HPV transcription/replication factor E2 (early 2) specifically up-regulates expression of the SR proteins SF2/ASF (splicing factor 2/alternative splicing factor), SRp20 and SC35 in infected epithelial cells. These SR proteins are essential for viral RNA processing. SF2/ASF is a proto-oncogene that is also up-regulated in a number of cancers. For example, SF2/ASF, together with SRp20 and SC35 is selectively upregulated in cervical tumours caused by persistent oncogenic HPV infection. However, the mode of SR protein up-regulation in tumours is different to the E2-directed transcriptional regulation in normal transient HPV infection. SR proteins could provide excellent targets for HPV antiviral therapy as well as anticancer therapy.
Introduction
Splicing involves removal of introns from pre-mRNAs and splicing together of exons to produce translatable mature mRNAs. It is an extremely complex process involving the pre-mRNA substrates, snRNAs (small nuclear RNAs) bound by PRP (pre-RNA processing) proteins to form snRNPs (small ribonucleoprotein) particles that form the core of the spliceosome, splicing-associated proteins and splicing regulatory proteins, including SR proteins (serine/arginine-rich proteins) (see below). The general removal of introns from a pre-mRNA is termed constitutive splicing. However, up to 94% of human pre-mRNAs may undergo alternative splicing, where a number of different mRNA isoforms can be produced from multi-exon genes by alternative inclusion or exclusion of 'cassette' exons [1] . Alternative splicing maximizes the coding capacity of the genome because the different RNA isoforms encode different proteins ( Figure 1A) . A number of different types of alternative splicing exist including choice of alternative cassette exons, intron retention and exon skipping. In intron retention an intron that is normally spliced out is retained and expressed as part of the mRNA; in exon skipping an exon is selectively excluded from the RNA. In each case translation of the mRNA will result in a protein with altered function. Alternative splicing is particularly important for organisms with limited genetic material, e.g. viruses,
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which can only package and carry a very small amount of genetic material. Many viruses use the cellular alternative splicing machinery to express a number of proteins from few genes [2] .
SR proteins and splicing
SR proteins are involved in regulation of constitutive and alternative splicing. All SR proteins derive from a single common ancestral splicing regulator and are highly related, being composed of the same two domains: an RNA recognition motif and a serine/arginine-rich domain that gives the proteins their name [3, 4] . SF2/ASF (splicing factor 2/alternative splicing factor) is considered the major SR protein in human cells. However, there are eight other classical SR proteins along with SF2/ASF, including SRp20, SC35, SRp40, SRp30c, SRp55, SRp75, SRp54 and 9G8 and a number of non-classical proteins, e.g. SRp38 and Tra2β [5] .
In constitutive splicing, SR proteins recruit components of the splicing machinery and help to define exons and introns by bridging splicing factors across the pre-mRNA [6] . Furthermore, interaction of SR proteins with the cap-binding complex at the 5 end of the RNA molecule and the polyadenylation machinery at the 3 end of the molecule facilitate definition and splicing of terminal exons [6, 7] . In alternative splicing, SR proteins bind to specific regulatory elements within exons (exonic sequence enhancers) or introns (intronic sequence enhancers) and stimulate splicing through recruitment of the splicing machinery [5] .
As splicing is an essential cellular process, it is very tightly regulated. Defects in splicing can lead to disease, including genetic disorders, autoimmune diseases and cancer. For and E7 open reading frames (ORFs) at the start of the early region of the HPV16 genome is shown at the top. Underneath are the four isoforms of E6 that can be produced through alternative splicing: full-length E6, E6*I, E6*II and E6*X [31] . The co-ordinates of the splice donor and acceptor sites with respect to the start of the genome are indicated by numbers. Start, start codon; stop, stop codon; P 97, HPV16 early promoter; SA, splice acceptor site; SD, splice donor site. Open boxes, exons; lines, introns.
example, aberrant splicing is responsible for the enhanced inclusion of exon 4 in the CD45 gene that leads to increased multiple sclerosis susceptibility [8, 9] , whereas an increased susceptibility to Type 1 diabetes is a result of a shift of one nucleotide in a 3 splice site of the OAS1 (2 ,5 -oligoadenylate synthetase 1) RNA that results in a longer protein product [10] .
Some members of the SR protein family regulate gene expression at other post-transcriptional levels. Whereas SR proteins such as SC35 and SRp40 are nucleus-confined, SF2/ASF, SRp20 and 9G8 shuttle between the nucleus and the cytoplasm [11] . This indicates that they possess cytoplasmic functions. For example, SR proteins have been shown to be involved in nuclear export of mRNAs [12] [13] [14] . Some SR proteins have been shown to have a regulatory role in mRNA stability as they can modulate stability and the nonsense-mediated decay process [15, 16] . Finally, SR proteins that traffic to the cytoplasm may also have a role in translation by binding to mTOR (mammalian target of rapamycin), which induces the phosphorylation of 4E-BP [eIF4E (eukaryotic initiation factor 4E)-binding protein], allowing eIF4E to initiate cap-dependent translation [17, 18] .
SR proteins in cancer
Recently SF2/ASF was shown to be a proto-oncogene [19] . It is expressed at high levels in a number of cancers including breast, prostate and cervical cancers [19] [20] [21] and is upregulated in breast cancer through amplification of its gene, SFRS1, which is found on chromosome 17q23 [19] . Evidence for its oncogenic function came from studies in which overexpression in NIH 3T3 cells caused colony formation in soft agar, whereas overexpression of other splicing factors, such as SC35, did not yield colony formation to the same extent. Moreover, in contrast with the effects of other SR proteins, SF2/ASF-overexpressing cells injected into nude mice formed large tumours. Furthermore, SF2/ASF co-operated with H-Ras to enhance cellular proliferation and appeared to protect cells from apoptosis induced by DNA damage and serum deprivation. Finally, SF2/ASF overexpression induced an oncogenic isoform, isoform 2, of S6K1 (S6 ribosomal protein kinase 1) [19] . S6K1 isoform 1 is the predominant form in normal cells and is involved in the mTOR pathway that regulates cell growth and apoptosis. Conversely, siRNA knockdown of SF2/ASF reduced S6K1 isoform 2 expression and resulted in loss of the tumour phenotype [19] . It remains to be seen whether SF2/ASF regulates other proteins involved in growth control and/or tumour invasion and metastasis. However, it is clear that SF2/ASF has classic tumour-promoting properties and due to the high degree of homology between different SR proteins it is likely that SF2/ASF is not unique amongst the SR proteins in having some role in oncogenesis.
HPV (human papillomavirus) infection and cancer
HPVs are small DNA viruses that infect mucosal and cutaneous epithelial cells. HPVs can be either 'high risk' or 'low risk' depending on whether they have the capacity to cause cancer [22] . The genomes of high-risk viruses, e.g. from HPV16 or HPV18, can sometimes integrate into the host genome and lead to malignant transformation of the infected cell. In contrast, low-risk HPV genomes, e.g. from HPV6 or HPV11, rarely integrate into host chromosomes. Therefore lesions induced by infection with a low-risk virus usually regress with time and there is only a very low risk of progression to malignancy. HPV replication is tightly linked to differentiation of the epithelium it infects (Figures 2A and 2B ). Virusinduced reactivation of the cell cycle in the differentiated epithelial layers allows HPV genome replication in the midlayers of the epithelium using the cellular DNA replication machinery [23] . This also results in the thickened epithelium characteristic of lesions caused by HPV. In a normal infection, HPV expresses at least eight proteins: six early proteins (E1, E2, E4, E5, E6 and E7) and two late proteins (L1 and L2) [24] . These are encoded by a complex suite of mRNAs that are the products of extensive constitutive and alternative RNA splicing [25, 26] . Examples of the types of alternative splicing events required to express the four isoforms of the virus oncoproteins E6 and E7 are shown in Figure 1(B) [27] . The virus transcription factor E2 regulates early protein expression. In a normal transient infection, E2 represses expression of E6 and E7 [28] . However, in cervical tumour cells where the HPV genome is irreversibly integrated, only the two viral oncoproteins, E6 and E7, are expressed ( Figure 2C ) due to loss or disruption of the remainder of the virus genome, including the E2 open reading frame [22] . In the absence of the E2 repressor, E6 and E7 expression levels are increased, their mRNAs are stabilized and the proteins co-operate to transform the cell and drive cellular proliferation [29] .
SR proteins and HPV infection
SF2/ASF expression in the normal cervical epithelium is typically restricted to the dividing cells of the basal layer (Figure 2A) . However, when the epithelium is infected by high-risk human papillomaviruses, such as HPV16, SF2/ASF is expressed at high levels in the mid-to-upper layers of the epithelium [30] (Figure 2B ). This unusual virus induction of cellular gene expression is due to the HPV E2 transcription factor. E2 binds and trans-activates the promoter of the SFRS1 gene encoding SF2/ASF resulting in a 4-8-fold increase in protein levels in differentiated epithelial cells [31] . A single null point-mutation in the E2 transactivation domain, in the context of the whole virus genome, when stably transfected into epithelial cells was sufficient to prevent the up-regulation of SF2/ASF [32] . HPV16 E2 has also been shown to specifically up-regulate SRp20 and SC35 [30] . Other high-risk HPV E2 proteins also regulate SF2/ASF [32] . This virus control of cellular RNA processing proteins seems to be essential for expression of some virus proteins because HPV-infected cells expressing a mutant E2 protein that cannot stimulate expression of SR proteins showed reduced levels of virus RNAs [32] . Importantly, levels of virus capsid proteins required for virion formation, transmission and spread were significantly reduced [28] . This indicates that SR proteins are required for virus protein expression in the mid-to-upper epithelial layers. SF2/ASF, SRp20 and SC35 are up-regulated not only during virus infection but also during cervical tumour progression [30] . Examination of cervical epithelia from patients with virus-induced malignant tumours revealed increased levels of these SR proteins throughout the epithelial layers [30] (Figure 2C ). SF2/ASF, SRp20 and SC35 levels were also selectively increased in a model of cervical cancer progression [30] . The model consists of four different cell lines: W12E, W12G, W12GPX and W12GPXY [33] (Figure 3A ). W12E cells contain around 100 episomal copies of the HPV16 genome, and represent HPV-infected epithelial cells, whereas W12G cells contain integrated copies of the HPV16 genome and represent the first stage in cervical tumour progression [34, 35] . Both W12E and W12G cells are immortal, but nontransformed, and retain the ability to differentiate in cell culture. W12GPX and W12GPXY cell lines, derived from W12G cells [33] , do not have the ability to differentiate in culture and are fully transformed. In particular, W12GPXY cells are highly invasive in tissue culture and form invasive tumours in nude mice [33] . Examination of SR protein expression in these cell lines revealed that levels of SF2/ASF, SRp20 and SC35 (but not other SR proteins, e.g. 9G8) appeared to increase with increasing tumorigenicity and, compared with W12G cells, were highest in the most transformed cell line, W12GPXY ( Figure 3B ). However, we have found that SF2/ASF, SRp20 and, to a lesser extent, SC35 protein levels are also activated in the non-transformed infected cell line W12E. At first glance this result is counterintuitive, but the answer possibly lies in two different modes of regulation of SR protein expression. In W12E cells, up-regulation is caused by the virus transcription factor E2 [32] . In W12GPXY cells HPV genomes have integrated into the host genome. This event abrogates expression of E2 so E2 cannot be the cause of SR protein up-regulation in these cervical cancer cells. We hypothesize that increased expression of a subset of SR protein in the transformed cell lines is due to chromosomal rearrangements resulting in amplification or activation of their genes. This is currently under investigation.
SR proteins as therapeutic targets
As SR proteins are up-regulated in a number of human cancers they may be excellent cancer therapeutic targets. Reducing SR protein expression to near basal levels may be sufficient to slow the course of malignancy for already progressed tumours or prevent further transformation of low-grade tumours. Anti-SR protein drugs may also be useful in treating HPV infection therapeutically. Although there is a vaccine available to prevent HPV infection, the vaccine is prophylactic so will be of no use to the millions of individuals already infected with HPV. If high levels of SF2/ASF expression are required for productive viral infection, attempting to reduce SR expression may limit production of new virus particles. The cervical epithelium is easily accessed and production of virus particles takes place only in the upper epithelial layers, so topically applied therapies are likely to work, at least for treatment of cervical lesions due to virus infection. One option is to use IDCs (indole derivative compounds) that inhibit the exonic splicing enhancer abilities of specific SR proteins [36] . It is thought that the inhibitors act by binding to the serine/arginine-rich domain in the SR protein and altering the phosphorylation status of the protein [36] . Changes in phosphorylation status could affect either recognition of exonic splicing enhancer elements or the protein's ability to bind the transportin-SR protein thus blocking export from the cytoplasm [36] .
The effect of SR protein inhibition by IDCs has already been investigated in the pathogenesis of other viral diseases. For example, MLV (murine leukaemia virus) is an RNA virus that produces one unspliced and one spliced mRNA during productive infection. This alternative splicing pattern is required to produce infectious virions. In an ex vivo replication assay, IDC-78 and IDC-13 efficiently inhibited the replication of MLV by reducing levels of spliced viral mRNAs [36] . Another compound, IDC-16, has been shown to inhibit SF2/ASF-mediated splicing of RNAs encoding HIV-1 regulatory proteins and thereby interfere with virion assembly [36] . HIV-1 requires SF2/ASF for viral mRNA splicing: a number of alternative 5 and 3 splice sites are used in order to produce mRNAs from the full-length viral pre-mRNA [37] . Bakkour et al. [38] demonstrated that IDC-16 inhibited several weak viral 3 splice sites and prevented production of multiple alternatively spliced mRNAs. There was no effect on cell viability or cellular RNA processing, but HIV-1 replication was inhibited, indicating that the drug acted selectively on viral mRNA processing [38] . The main concern with targeting essential cellular proteins in this way is possible off-target effects that may occur due to alterations in splicing of mRNAs encoding essential cellular proteins. However, there may be redundancy in SR protein function and the Keriel et al. [36] study reported no serious global side-effects, at least in their mouse model system. Further study of the effects of SR protein inhibition on normal cellular processes and during disease are required. However, targeting SR proteins in cancers and viral infections opens up a very exciting new prospect for treatment of disease.
